Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment...
Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancer
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
To evaluate the effect of regorafenib on soluble MHC class I polypeptide-related sequence A (MICA) (sMICA) level in vitro. In addition, we clinically examined whether its plasma levels were associated with regorafenib activity in terms of progression-free survival (PFS) in patients with CRC.
Human CRC cell line HCT116 and HT29 cells were treated...
Alternative Titles
Full title
Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_beacc506008f4c9b88f6ed901d1eff5b
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_beacc506008f4c9b88f6ed901d1eff5b
Other Identifiers
ISSN
1471-2407
E-ISSN
1471-2407
DOI
10.1186/s12885-022-09512-5
